Zusammenfassung
Die chronische myeloische Leukämie (CML) wird durch die onkogene BCR-ABL Translokation verursacht. Diese Erkenntnis führte – erstmals in der Onkologie – zur rationalen Entwicklung eines spezifischen Onkogeninhibitors. Heute kann durch die BCR-ABL Hemmung das Überleben von Patienten mit CML in chronischer Phase dem der altersgleichen, gesunden Normalbevölkerung angeglichen werden. Das Prinzip der molekularen Signaltransduktionsinhibition hat sich seither in der gesamten Onkologie durchgesetzt. Das molekulare Verständnis der CML Genetik und der darauf basierenden Therapie ist lehrreich für jeden Arzt, weil man hieran die Prinzipien einer molekularen Therapie in der Medizin verstehen lernt.
This is a preview of subscription content, log in via an institution.
Literatur
Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884
Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233(4760):212–214
Bradeen HA, Eide CA, O’Hare T et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108(7):2332–2338
Burchert A, Neubauer A (2011) Chronic myeloid leukemia. Diagnostics, therapy and future strategy. Internist (Berl) 52(3):283–293
Burchert A, Müller MC, Kostrewa P et al (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28(8):1429–1435
Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038–1042
Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876–880
Hochhaus A (2002) Detection and quantification of leukemia-specific rearrangements. Methods Mol Med 68:67–96
Hochhaus A, Kreil S, Corbin A et al (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293(5538):2163
Hochhaus A, O’Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054–1061
Mahon F-X, Réa D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029–1035
Nowell PC, Hungerford DA (1961) Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 27:1013–1035
O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004
O’Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65(11):4500–4505
O’Hare T, Zabriskie MS, Eiring AM, Deininger MW (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12(8):513–526
Preudhomme C, Guilhot J, Nicolini FE et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363(26):2511–2521
Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22(3):295–302
Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290–293
Saussele S, Lauseker M, Gratwohl A et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880–1885
Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401
Simonsson B, Gedde-Dahl T, Markevärn B et al (2011) Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118(12):3228–3235
Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2):129–141
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Burchert, A. (2014). Chronische myeloische Leukämie. In: Lehnert, H., et al. SpringerReference Innere Medizin. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54676-1_464-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-54676-1_464-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-54676-1
eBook Packages: Springer Referenz Medizin